AKT1 and Cirrhosis: Serelaxin treatment (4 μg/h s.c. for 72 h) increased p-eNOS and p-AKT protein in whole kidney in both rat cirrhosis models (Fig 4A–4F) and augmented NOS activity to levels approximating those of controls (CCl4: serelaxin 122% ± 31% of control kidney NOS activity versus vehicle 5% ± 3%; d = 114, 95% CI 6.45, 223, p = 0.035; BDL: serelaxin 86% ± 22% versus vehicle 26% ± 11%; d = 60, 95% CI 4.2, 115, p = 0.032) (Fig 4G and 4H).